Antibodies to interferon-α in treated cancer patients: Incidence and significance

Journal of Interferon and Cytokine Research

Volumn 17, Issue 3, 1997, Pages 141-143

  McKenna, Rachel M ^a,c   Oberg, Kjell E ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ALPHA2A INTERFERON; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CANCER; CANCER RECURRENCE; PRIORITY JOURNAL;

EID: 0030936629     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1997.17.141     Document Type: Article

References (25)

1. FIGLIN, R.A., and ITRI, L.M. (1988). Anti-interferon antibodies: a perspective. Semin Hematol 25(Suppl 3), 9.
2. GRANDER, D., OBERG, K., LUNDQUIST, M.L., JANSON, E.T., ERIKSSON, B., and EINHORN, S. (1990). Interferon enhancement of 2′,5′-oligodenylate synthetase in mid-gut carcinoid tumors. Lancet 336, 337-340.
3. OBERG, K. (1994). Autoimmunity and antibodies to interferons in patients with carcinoid tumors - clinical consequences. J. Interferon Res. 14, 215-216.
4. VON WUSSOW, P., HEHLMANN, R., HOCHHAUS, T., JAKSCHIES, D., NOLTE K., PRUMMER, O., ANSARI, H., HASFORD, J., HEIMPEL, H., and DEICHER, H. (1994). Roferon (rIFN-α2a) is more immunogenic than Intron A (rIFN-α2b) in patients with chronic myelogenous leukemia. J. Interferon Res. 14, 217-219.
5. ANTONELLI, G., CURRENTI, M., TURRIZIANI, O., and DIANZANI, F. (1991). Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163, 882-885.
6. ANTONELLI, G., and DIANZANI, F. (1993). Antibodies to interferon alpha in patients. Arch. Virol. 8(Suppl.), 271-277.
7. BRESLOW, N.E., and DAY, N.E. (1980). Classical methods of analysis of grouped data. In: Statistical Methods in Cancer Research. The Analysis of Case-Control Studies. N.E. Breslow and N.E. Day (eds.) Lyon: International Agency for Research on Cancer, Vol. 1, p. 122.
8. ITRI, L.M., CAMPION, M., DENNIN, R.A., PALLERONI, A.V., GUTTERMAN, J.U., GROOPMAN, J.E., and TROWN, P.W. (1987). Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha-2a by intramuscular injection. Cancer 59, 668-674.
9. KROWN, S.E., REAL, F.X., EINZIG, A.I., KRIM, M., TWOEN, P., and OETIGEN, H.F. (1985). Treatment of Kaposi's sarcoma and renal cell carcinoma with recombinant leukocyte A interferon. In: The Biology of the Inferferon System 1984. Kirchner, H., Schellekens, H., eds. New York: Elsevier Science, pp. 523-527.
10. STEIS, R.G., SMITH, J.W., URBA, W.J., CLARK, J.W., ITRI, L.M., EVANS, L.M., SCHONENBERGER, C., and LONGO, D.L. (1988). Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318, 1409-1413.
11. VON WUSSOW, P., FREUND, M., BLOCK, B., DIEDRICH, H., POLIWODA, H., and DEICHER, H. (1987). Clinical significance of anti-IFN-α antibody titres during interferon therapy. Lancet 2, 635-636.
12. QUESADA, J.R., ITRI, L., and GUTTERMAN, J.U. (1987). Alpha interferons in hairy cell leukemia (HCL). A five-year follow-up in 100 patients. J. Interferon Res. 7, 678.
13. VON WUSSOW, P., PRALLE, H., JAKSHIES, D., HOCHKEPPEL, H.K., and DEICHER, H. (1989). Effective treatment of recombinant interferon alpha-2 (IFN-α) antibody-positive hairy cell leukemia (HCL) patients with natural interferon alpha (nIFN) (Abstract). American Society of Hematology Annual Meeting.
14. BERMAN, E., HEILER, G., KEMOIN, S., GEE, T., TRAN, L.L., and CLARKSON, B. (1990). Incidence of response and long-term follow-up in a patient with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75, 839-845.
15. FREUND, M., VON WUSSOW, P., DIEDRICH, H., EISERT, R., LINK, H., WILKE, H., BUCHHOLZ, F., LEBLANC, S., FONNTSCH, C., DEICHER, H., and POLIWODA, H. (1989). Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Hematol. 72, 350-356.
16. OBERG, K., ALM, G., MAGNUSSON, A., LUNDQUIST, G., THEORDORSSON, E., WIDE, L., and WILANDER, E. (1989). Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl. Cancer Inst. 81, 531-535.
17. QUESADA, J.R., RIOS, A., SWANSON, D., TROWN, P., and GUTTERMAN, J.U. (1985). Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3, 1522-1528.
18. PRUMMER, O. (1993). Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2a in an adjuvant multicenter trial. Cancer 71, 1828-1834.
19. McSWEENEY, E.N., GILES, F.J., WORMAN, C.P., JEWEL, A.P., TSAKONA, C.P., HOFFBRAND, A.V., MEHTA, A.B., NEWLAND, A.C., CAWLEY, J.C., GALVANI, D., SINGER, C.R.J., GRANT, I.R., NORFOLK, D.R., and GOLDSTONE, A.H. (1993). Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br. J. Haematol. 85, 77-83.
20. DAVIS, G.L., BALART, L.A., SCHIFF, E.R., LINDSAY, K., BODENHEIMER, H.C., PERILLO, R.P., CAREY, W., JACOBSON, I.M., PAYNE, J., DIENSTAG, J.L., VAN THIEL, D.H., TAMBURRO, C., LEFKOWITCH, J., ALBRECHT, J., MESCHIEVITZ, C., ORETEGO, T.J., and GIBAS, A. (1989). Treatment of chronic hepatitis C with recombinant interferon alfa. N. Engl. J. Med. 321, 1201-1506.
21. PERILLO, R.P., SCHIFF, E.R., DAVIS, G.L., BODENHEIMER, H.S., LINDSAY, K., PAYNE, J., DIENSTAG, J.L., O'BRIEN, C., TAMBURRO, C., JACOBSON, I.M., SAMPLINER, R., FEIT, D., LEFKOWITCH, H., KUHNS, M., MESCHIEVITZ, C., SANGHVI, B., ALBRECHT, J., and GIBAS, A. 1990. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 323, 295-301.
22. LOK, A.S.F., LAI, C.-L., and LEUNG, E.K.Y. (1990). Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12, 1266-1270.
23. PORRES, J.C., CARRENO, V., RUIZ, M., MARRON, J.A., and BARTOLOME, J. (1989). Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J. Hepatol. 8, 351-357.
24. WORLD HEALTH ORGANIZATION EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION. (1983). Standardization of interferons. WHO Tech. rep. ser. 687, 50-52.
25. ANDZHAPARIDZE, O.G., AYRES, J.J., DEMAEYER, E., FINTER, N., FRIEDMAN, R., GROSSBERG, S.E., KRAMER, S.M., LAUGHLIN, C.A., LEIBOWITZ, P.J., MEAGER, A., NARACHI, M., TRUEHAFT, M., VILCEK, J., YAMAZAKI, S., ZOON, K., ESPARZA, J., GRACHEV, V., and SIZARET, P. (1988). Standardization of interferons (Report of a WHO Consultation). WHO tech. rep. ser. 771, 37-87.